Diffuse Intrinsic Pontine Glioma (DIPG)

Status: draft · Last updated 2026-11-13 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • Prognosis: median OS about 11 months. 2-year OS about 10%, and 5-year OS 2% .
  • Diagnosis: a short history, the triad (CN VI/VII, ataxia, long tracts), and an expansile T2-bright pons engulfing the basilar artery .
    • Ring enhancement and necrosis are bad signs.
    • Age under 3 and a longer history are better signs .
  • Biopsy is safe: 96% diagnostic, 0.6% permanent morbidity and 0.6% mortality.
    • It is increasingly done for profiling and trials .
  • Biology: H3 K27M or loss of H3K27me3 in essentially all cases.
    • H3.1 (often with ACVR1) does better than H3.3 .
  • Therapy:
    • Radiation: 54 Gy, or hypofractionated with equal survival .
    • Re-irradiation: helps at progression .
    • Chemotherapy: fails; temozolomide 1-year EFS was 14% .
    • ONC201: FDA-approved in 2025 for recurrent H3 K27M DMG .
    • CAR T: an early signal .

Landmark papers

  • International DIPG registry (Hoffman et al., J Clin Oncol 2018): 1,008 registry patients. 10% survived 2 years or more, and 5-year OS was 2% .
  • ACNS0126 (Cohen et al., Neuro Oncol 2011): temozolomide added to radiation in 63 children. 1-year EFS was 14% vs the historical 21.9% .

DIPG is a diffusely infiltrating glioma of the pons and the deadliest solid tumor of childhood. Median survival is about 11 months, and only 2% are alive at 5 years . In WHO 2021 terms, almost all DIPGs are diffuse midline glioma, H3 K27-altered . "DIPG" remains the clinical and radiologic name.

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:dipg:f188a37a83ce8896© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Diffuse intrinsic pontine glioma: midsagittal posterior fossa with an expanded, diffusely infiltrated pons bulging forward to engulf the basilar artery and compressing the fourth ventricle; and an axial T2-style image with a hyperintense tumor occupying more than half of the pons and encasing the basilar artery flow void(A) MIDSAGITTAL POSTERIOR FOSSA (ANTERIOR LEFT)midbrainpons (expanded),diffusely infiltratedby tumorbasilar arteryengulfed by theanterior bulgeclivusfourth ventricle(compressed)cerebellummedulla(B) AXIAL T2 MRI AT THE PONS (ANTERIOR UP)anteriorT2-hyperintense tumoroccupying >50% of thepontine axial areabasilar artery encased(flow void)fourth ventricle(compressed)cerebellumtemporal lobepetrous ridgeprepontine cisternand clivusschematic; not to scale
Diffuse intrinsic pontine glioma. (A) Midsagittal view: an infiltrative tumor expands the pons, bulges anteriorly to engulf the basilar artery, and compresses the fourth ventricle. (B) Axial T2-weighted MRI at the pons: a hyperintense tumor fills most of the pontine cross-section and encases the basilar artery flow void. Not to scale.

Presentation and diagnosis

Biopsy: the shift

Molecular biology

Treatment

Neurosurgical roles

Related topics

References

  1. Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, et al. Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG Registries. J Clin Oncol 2018;36(19):1963–1972. doi:10.1200/JCO.2017.75.9308. PMID 29746225. verified
  2. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106. PMID 34185076. verified
  3. Castel D, Philippe C, Calmon R, et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 2015;130(6):815–827. doi:10.1007/s00401-015-1478-0. PMID 26399631. verified
  4. Janssens GO, Jansen MH, Lauwers SJ, et al. Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis. Int J Radiat Oncol Biol Phys 2013;85(2):315–320. doi:10.1016/j.ijrobp.2012.04.006. PMID 22682807. verified
  5. Jansen MH, Veldhuijzen van Zanten SE, Sanchez Aliaga E, et al. Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro Oncol 2015;17(1):160–166. doi:10.1093/neuonc/nou104. PMID 24903904. verified
  6. Hamisch C, Kickingereder P, Fischer M, et al. Update on the diagnostic value and safety of stereotactic biopsy for pediatric brainstem tumors: a systematic review and meta-analysis of 735 cases. J Neurosurg Pediatr 2017;20(3):261–268. doi:10.3171/2017.2.PEDS1665. PMID 28621573. verified
  7. Gupta N, Goumnerova LC, Manley P, et al. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol 2018;20(11):1547–1555. doi:10.1093/neuonc/noy070. PMID 29741745. verified
  8. Pfaff E, El Damaty A, Balasubramanian GP, et al. Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. Eur J Cancer 2019;114:27–35. doi:10.1016/j.ejca.2019.03.019. PMID 31022591. verified
  9. Mackay A, Burford A, Carvalho D, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 2017;32(4):520–537.e5. doi:10.1016/j.ccell.2017.08.017. PMID 28966033. verified
  10. Shariff N, Moreno AS, Bennett J, et al. Re-irradiation for children with diffuse intrinsic pontine glioma and diffuse midline glioma. Radiother Oncol 2025;207:110865. doi:10.1016/j.radonc.2025.110865. PMID 40139463. verified
  11. Cohen KJ, Heideman RL, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol 2011;13(4):410–416. doi:10.1093/neuonc/noq205. PMID 21345842. verified
  12. Jansen MH, van Vuurden DG, Vandertop WP, Kaspers GJ. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev 2012;38(1):27–35. doi:10.1016/j.ctrv.2011.06.007. PMID 21764221. verified
  13. Venneti S, Kawakibi AR, Ji S, et al. Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways. Cancer Discov 2023;13(11):2370–2393. doi:10.1158/2159-8290.CD-23-0131. PMID 37584601. verified
  14. Blair HA. Dordaviprone: first approval. Drugs 2026;86(1):101–109. doi:10.1007/s40265-025-02252-3. PMID 41138047. verified
  15. Monje M, Mahdi J, Majzner R, et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature 2025;637(8046):708–715. doi:10.1038/s41586-024-08171-9. PMID 39537919. verified
  16. Vitanza NA, Ronsley R, Choe M, et al. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat Med 2025;31(3):861–868. doi:10.1038/s41591-024-03451-3. PMID 39775044. verified

Verification (2026-11-13): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts.

Caveats: